The Multidisciplinary Team Approach: Optimizing Breast Cancer Therapy in the Targeted Treatment Era
Joyce O’Shaughnessy, MD
Co-Chair, Breast Cancer Research
Chair of Breast Cancer Prevention Research
Baylor-Sammons Cancer Center
Reshma Lillaney Mahtani, DO
Assistant Professor, Division of Hematology/Oncology
Sylvester Comprehensive Cancer Center
University of Miami Health System
This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.
This CME initiative is designed to meet the educational needs of nurses, pharmacists, medical oncologists, and other healthcare providers involved in the treatment of patients with breast cancer.
Upon the completion of this program, attendees should be able to:
- Describe the antitumorigenic mechanisms of the CDK 4/6 inhibitors in hormone receptor-positive breast cancer
- Discuss the CDK 4/6 inhibitor clinical trial data for patients with HR+, HER-2 negative advanced breast cancer across multiple lines of therapy
- Review nurses’ and pharmacists’ roles in recognizing breast cancer treatment- related adverse events while optimizing patient medication persistence
- Explain the patient’s and health care team’s responsibilities to optimize outcomes through ongoing education and communication to support adherence to breast cancer treatments
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in treating and managing patients with breast cancer. CNE Credits: 1.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Joyce O’Shaugnessy reports consulting with Celgene, Pfizer, AstraZeneca, and Novartis.
Dr. Reshma Lillaney Mahtani, reports that she has served as a consultant for Pfizer and Novartis.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group, has nothing to disclose.
Flavia Piazza, PhD, VP Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
Participants will receive their certificate via email within 30 days.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: November 27, 2018
EXPIRATION DATE: November 27, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.